Guobang Pharmaceutical announced on September 15 that the company recently learned from an inquiry on the “Raw and Auxiliary Package Registration Information” platform of the Drug Evaluation Center of the State Drug Administration that the joint review and approval result of the “cultured dimyristate glyceride” pharmaceutical excipient CDE and formulation submitted by Zhejiang Guobang Pharmaceutical Co., Ltd., a wholly-owned subsidiary, was A. The registration status of excipients changed to A status, which met the supply conditions for commercial production of downstream customer formulations.

Guobang Pharmaceutical announced on September 15 that the company recently learned from an inquiry on the “Raw and Auxiliary Package Registration Information” platform of the Drug Evaluation Center of the State Drug Administration that the joint review and approval result of the “cultured dimyristate glyceride” pharmaceutical excipient CDE and formulation submitted by Zhejiang Guobang Pharmaceutical Co., Ltd., a wholly-owned subsidiary, was A. The registration status of excipients changed to A status, which met the supply conditions for commercial production of downstream customer formulations.